Additional Information Synonyms- Coluracetam, BCI-540, MKC-231
IUPAC- N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide
Formula C19H23N3O3
Molecular weight 341.404 g/mol
CAS 135463-81-9
Appearance- No
Purity- No

In stock
From : €167.11

Coluracetam is a racetam compound that Japanese pharmaceutical company Mitsubishi Tanabe derived from Piracetam in 2005. The patent for the compound was later transferred to BrainCells Inc., a firm that develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. The firm now conducts most of the clinical testing for the compound, and latest research results indicate that the compound shows great potential for treating specific CNS disorders and retinal and optic nerve damage.


As with many of the racetam compounds, Coluracetam elevates the body’s choline uptake, while also increasing the uptake in damaged neurons. The compound targets and interacts with the high affinity choline uptake (HACU) process, which is the mechanism for absorbing choline into neurons. The uptake increase happens during the Acetylcholine synthesis process. Because Coluracetam improves the preservation of choline during this process, the result is that a larger amount of choline is converted into Acetylcholine. The beneficial yield from the process incudes an increased amount of attention and alertness, along with improvements to memory. Research shows that Coluracetam also improves α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) potentiation, a receptor for glutamate that aids in synaptic transmission in the central nervous system process that boosts alertness and cognitive functions.


Studies show that Coluracetam shows the greatest potential in treating both general anxiety and clinical depression. Other studies show that the compound also shows promise in the treatment of optic nerve and retinal injury.


BrainCells Inc. started testing the effects of Coluracetam on rats after acquiring the patent from Mitsubishi Tanabe. Research results indicate there were marked improvement in the rodent’s eyesight, anxiety processing and cognitive functioning after testing with the compound.


Research conducted on Coluracetam indicated that it is beneficial in the treatment of retinal and optic nerve injuries. It is also associated with other optic benefits such as visual recognition and vividness and improved color vision.


Researchers reported that a dosage of 240 mg of the compound split into three doses of 80 mg daily was beneficial in treating major clinical depression co-morbid with generalized anxiety disorder.


A study using Coluracetam showed improvement to memory in rats who were given a neuron-specific neurotoxin. The rats were later able to maneuver through the standardized Morris Water Maze up to 72 hours after the last dosage of the compound.


Currently there have not been any negative side effects or toxicity reported with Coluracetam use. At the end of clinical trials using a daily dose of 240 mg per day (given three equal administrations) no side effects were reported. This dosage amount was the highest suggested dosage of the compound used in any of the trials to date.


If you haven’t used a nootropic before, you may develop headaches after use, which is commonly seen in first time users. And just like most of the compounds in the Racetam family, Coluracetam stacks excellently with Choline for an extra boost to memory and cognitive functioning. The recommended doses for Choline is 250 mg to 750 mg daily if you’re using CDP Choline and 300 mg to 600 mg daily if you’re stacking with Alpha GPC.
More Information
Write Your Own Review
You're reviewing:Coluracetam
Your Rating